NewVac

NewVac is engaged in the research and development of personalized and combination approaches to cancer therapy. Under a license agreement with Janssen, a subsidiary of the Johnson & Johnson Group, Newvac has obtained the right to develop, research and commercialize quisinostat, which is an inhibitor of histone deacetylases (HDACs). Quisinostat has highly specific antitumor activity and relatively low toxicity, which makes it a promising drug for oncotherapy.

One of the company’s projects is the drug product AVIONCO®, which is being developed in collaboration with Janssen Pharmaceutica NV. AVIONCO® is an oral histone deacetylase inhibitor (HDACi). The product has unique pharmacokinetic properties for its clours, including rare, difficult-to-treat childhood cancers such as synovial sarcoma and glioma.

Phase II clinical trials in platinum-resistant ovarian cancer in combination with chemotherapy have been successfully completed. AVIONСO® demonstrated high efficacy and a favourable safety and tolerability profile. The research results were presented to the world community at the leading international oncology congresses ESMO 2016 (European Society for Medical Oncology) and ASCO 2017 (American Society of Clinical Oncology).

The priority of NewVac is to create effective innovative approaches to the treatment of oncological diseases based on the latest advances in molecular biology. The project is supported by the Ministry of Industry and Trade of the Russian Federation within the framework of the Federal Target Programme ‘Development of the Pharmaceutical and Medical Industry of the Russian Federation for the Period to 2020 and Beyond’.